Nabriva Therapeutics (NBRV) Competitors

INmune Bio (NASDAQ:INMB) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations.

Which has more volatility and risk, INMB or NBRV?

INmune Bio has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.

Does the media refer more to INMB or NBRV?

In the previous week, INmune Bio had 3 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 4 mentions for INmune Bio and 1 mentions for Nabriva Therapeutics. INmune Bio's average media sentiment score of 1.47 beat Nabriva Therapeutics' score of 0.00 indicating that INmune Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nabriva Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend INMB or NBRV?

INmune Bio presently has a consensus target price of $22.80, indicating a potential upside of 192.50%. Given INmune Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe INmune Bio is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do institutionals & insiders believe in INMB or NBRV?

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 35.2% of INmune Bio shares are held by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer INMB or NBRV?

Nabriva Therapeutics received 249 more outperform votes than INmune Bio when rated by MarketBeat users. However, 76.60% of users gave INmune Bio an outperform vote while only 54.58% of users gave Nabriva Therapeutics an outperform vote.

Company	Underperform	Outperform
INmune Bio	Outperform Votes 144 76.60%	Underperform Votes 44 23.40%
Nabriva Therapeutics	Outperform Votes 393 54.58%	Underperform Votes 327 45.42%

Is INMB or NBRV more profitable?

INmune Bio has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. INmune Bio's return on equity of -117.48% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-117.48%	-78.96%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Which has preferable valuation and earnings, INMB or NBRV?

INmune Bio has higher earnings, but lower revenue than Nabriva Therapeutics. INmune Bio is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$14K	12,797.16	-$30.01M	-$2.11	-3.69
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

Summary

INmune Bio beats Nabriva Therapeutics on 15 of the 18 factors compared between the two stocks.